Trastuzumab biosimilar (Peking Union Medical College Hospital)

N/A

Report date: 2025/08/08 20:01:41

Base Information

Drug NameTrastuzumab biosimilar (Peking Union Medical College Hospital)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsRectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPeking Union Medical College Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital
Inactive CompaniesN/A
Active IndicationsRectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A